Vanguards of Health Care by Bloomberg Intelligence

Bloomberg
  • 5.0（3則評分）
  • 投資
  • 隔週更新

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

  1. 2 天前

    AKASA's AI Recovers Millions for Health Systems by Simplifying Complexity

    “American medicine is the best in the world, but the American health-care system is not,” Akasa CEO Malinka Walaliyadde says. In this Vanguards of Health Care episode, Walaliyadde joins Bloomberg Intelligence analyst Jonathan Palmer to explore how Akasa is tackling the chaos of revenue-cycle management with AI. He explains why America’s overlapping payment models create inefficiency, how large-language models read massive patient records in minutes and why custom models built for each health system outperform off-the-shelf AI. They also discuss Akasa’s performance-based business model and the path toward real-time payer-provider communication, as well as the role that grit and conviction play in building a transformative company. See omnystudio.com/listener for privacy information.

    52 分鐘

  2. 4 天前

    From the NIH to ModeX, Dr. Elias Zerhouni on Science, Politics, and Innovation

    The worst thing that can happen in health-care and biomedical research is politics getting involved in choosing what research needs to be done for what disease, Dr. Elias Zerhouni tells Bloomberg Intelligence analyst Sam Fazeli, explaining how mixing science and politics weakens innovation and public trust. On this episode of the Vanguards of Health Care podcast, Zerhouni, a former NIH director and vice chairman of OPKO Health, unpacks his new book Disease Knows No Politics, warns against cutting US research funding and explains why immigration is vital for scientific leadership. He also dives into OPKO and ModeX’s cutting-edge work on multivalent vaccines and multi-specific antibodies that could change the treatment landscape.   See omnystudio.com/listener for privacy information.

    50 分鐘

  3. 8月28日

    Zimmer Biomet’s Ivan Tornos is Investing in the Next Chapter of Orthopedics with Arnold

    “We are reinventing ourselves. We don’t want to be just a legacy orthopedic company and I think we’re driving with the same enthusiasm as Arnold Schwarzenegger,” Zimmer Biomet Chairman, President and CEO Ivan Tornos tells Bloomberg Intelligence. In this Vanguards of Health Care episode, Tornos sits down with BI analyst Matt Henriksson for an in-depth interview about Zimmer Biomet and the strategic initiatives made through internal developments and key acquisitions, including Paragon 28 and Monogram, to accelerate its weighted average market growth rate (WAMGR). He also discusses the current orthopedic landscape and the opportunities arising from the shift to the ambulatory surgical center (ASC) setting, as well as his relationship with Arnold Schwarzenegger as Chief Movement Officer. See omnystudio.com/listener for privacy information.

    38 分鐘

  4. 8月22日

    Cognito Can Stimulate Brain Activity with Non-Invasive Gamma Waves

    “If you can drive the brain’s naturally occurring activity, what you can get is the biologic expression that is important for brains to maintain and protect themselves,” Cognito Therapeutics’ CEO Christian Howell tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Howell sits down with BI analyst Matt Henriksson to discuss the company and its Spectris device — a non-invasive therapeutic intervention designed to use gamma waves to preserve brain structure and function, starting with Alzheimer’s patients. He also highlights the promise of Cognito’s Hope study and reflects on how his time in the Navy and at Medtronic under former CEO Omar Ishrak shaped his “fidelity to the mission” leadership mantra. See omnystudio.com/listener for privacy information.

    44 分鐘

  5. 8月14日

    HistoSonics Provides Ultrasound Options to Treat Tumors

    “Unlike radiation therapy that's got toxicity to it as it enters the body and exits the body and leaves large areas of necrotic tissue, histotripsy is very different in that there's generally no damage going in or going out.” HistoSonics’ CEO Mike Blue explains about the Edison system. He then in depth with BI analyst Matt Henriksson on how the Edison histotripsy technology destroys targeted cancer cells, how it differentiates from other cancer treatment options, and how the company plans to expand the use of Edison from lung cancer to kidney, pancreas and prostate indications. Also tune in to learn how the recent acquisition announcement can accelerate its momentum to build out the clinical data and commercialization of Edison. See omnystudio.com/listener for privacy information.

    37 分鐘

  6. 8月7日

    Inside GHO Capital’s Thesis on Mid-Market Innovation

    “We don’t just invest — we bring knowledge, network and opportunity,” says Edward De Nor, partner at GHO Capital, as he joins Bloomberg Intelligence analyst Jonathan Palmer to discuss how the firm identifies and scales mid-market health-care companies that enable better, faster, more accessible care. He explains GHO’s investment thesis, its “picks and shovels” strategy and how innovation, not disruption, fuels compounding growth. The two explore case studies like BioAgilytix, the role of AI as an enabler and why boardrooms should obsess over the customer, not just the P&L. See omnystudio.com/listener for privacy information.

    43 分鐘

  7. 7月31日

    Ultromics Can Find Hard-to-Detect Heart Failure with the Power of AI

    “When a patient comes in for a routine outpatient echo, we’ll be able to help with diagnosis and reduce the misdiagnosis at that point, number one,” Ultromics’ Founder and CEO Ross Upton explains to Bloomberg Intelligence analyst Matt Henriksson about the initial benefits of EchoGo for heart failure and cardiac amyloidosis. In this episode of the Vanguards of Health Care podcast, Upton also delves into the future of diagnosing and treating heart failure with artificial intelligence, saying it can additionally “really accurately phenotype them, and so the clinician would understand after the echo is done what treatments or what next diagnostic tests the patient needs, and they would understand it there and then without having to go through and try and figure out the pieces of the puzzle.” Also tune in to learn how Ultromics plans to use to recently announced Series C financing as it commercializes EchoGo for heart failure and cardiac amyloidosis. See omnystudio.com/listener for privacy information.

    38 分鐘

  8. 7月24日

    How the Mark Foundation is Rebuilding the Cancer R&D Model

    “I like the label ‘new operating system.’ I think that does capture well what we're trying to do here,” says Dr. Ryan Schoenfeld, CEO of the Mark Foundation. In this episode of Vanguards of Health Care, Schoenfeld joins Bloomberg Intelligence analyst Sam Fazeli to explore how the foundation is redesigning cancer research through global collaboration, platform thinking and a bold portfolio approach. They discuss the Foundation’s growing international footprint, why basic research is increasingly under threat in the US, and where new breakthroughs — including solid tumor CAR-T and glioblastoma — may emerge in the next five years. See omnystudio.com/listener for privacy information.

    43 分鐘
顯示全部 (104)

評分與評論

5
（滿分 5 顆星）
3 則評分

簡介

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

資訊

你可能也會喜歡